Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review

Rokas Navickas1,2†, Diane Gal3†, Aleksandras Laucevičius1,2, Agné Taparauskaitė1, Monika Zdanytė4, and Paul Holvoet3*

1Faculty of Medicine, Vilnius University, Vilnius, Lithuania; 2Vilnius University Hospital Santariskij Klinikos, Vilnius, Lithuania; 3Department of Cardiovascular Sciences, Atherosclerosis and Metabolism Unit, KU Leuven, Leuven, Belgium; and 4Universitäts Klinikum Tübingen, Tübingen, Germany

Received 14 March 2016; revised 28 April 2016; accepted 19 May 2016; online publish-ahead-of-print 29 June 2016

Abstract

The aim of the present study is to identify microRNAs (miRs) with high potential to be used as biomarkers in plasma and/or serum to clinically diagnose, or provide accurate prognosis for survival in, patients with atherosclerosis, coronary artery disease, and acute coronary syndrome (ACS). A systematic search of published original research yielded a total of 72 studies. After review of the risk of bias of the published studies, according to Cochrane Collaboration and the QUADAS Group standards, 19 studies were selected. Overall 52 different miRs were reported. In particular, miR-133a/b (5 studies), miR-208a/b (6 studies), and miR-499 (7 studies) were well studied and found to be significant diagnostic and/or prognostic markers across different cardiovascular disease progression stages. miR-1 and miR-145b are potential biomarkers of ACS; miR-1 with higher sensitivity for all acute myocardial infarction (AMI), and miR-145 for STEMI and worse outcome of AMI. But when miRs were studied across different ACS study populations, patients had varying degrees of coronary stenosis, which was identified as an important confounder that limited the ability to quantitatively pool the study results. The identified miRs were found to regulate endothelial function and angiogenesis (miR-1, miR-133), vascular smooth muscle cell differentiation (miR-133, miR-145), communication between vascular smooth muscle and endothelial cell to stabilize plaques (miR-145), apoptosis (miR-1, miR-133, miR-499), cardiac myocyte differentiation (miR-1, miR-133, miR-145, miR-208, miR-499), and to repress cardiac hypertrophy (miR-133). Their role in these processes may be explained by regulation of shared RNA targets such as cyclin-dependent kinase inhibitor 1A (or p21), ETS proto-oncogene 1, fascin actin-bundling protein 1, hyperpolarization-activated cyclic nucleotide-gated potassium channel 4, insulin-like growth factor 1 receptor LIM and SH3 protein 1, purine nucleoside phosphorylase, and transgelin 2. These mechanistic data further support the clinical relevance of the identified miRs. miR-1, miR-133a/b, miR-145, miR-208a/b, and miR-499(a) in plasma and/or serum show some potential for diagnosis of cardiovascular disease. However, biased selection of miRs in most studies and unexplained contrasting results are major limitations of current miR research. Inconsistencies need to be addressed in order to definitively identify clinically useful miRs. Therefore, this paper presents important aspects to improve future miR research, including unbiased selection of miRs, standardization/normalization of reference miRs, adjustment for patient comorbidities and medication, and robust protocols of data-sharing plans that could prevent selective publication and selective reporting of miR research outcomes.

Keywords

Circulating microRNA • Biomarkers • Coronary artery disease • (Disease) Progression • Acute coronary syndrome

1. Introduction

MicroRNAs (miRs) are endogenous, non-coding, and small (18–22 nucleotides) RNA molecules. miRs are recruited to the RNA-induced silencing complex (RISC) and regulate the output of protein-coding genes through diverse mechanisms.1 The interaction of miRs with the 3’ untranslated region (3’ UTR) of protein-coding genes is considered as the main mechanism, which usually leads to a decrease in protein
output either by mRNA degradation or by translational repression.\textsuperscript{2} Recent studies have also suggested that miRs can interact with the 5’ UTR of protein-coding genes via complementarity and cause translational repression\textsuperscript{1} or activation of the targeted proteins.\textsuperscript{4} Similarly, miRs can also target the coding sequence and repress the translation of targeted genes.\textsuperscript{5} Moreover, some miRs can interact with regulatory protein complexes, such as argonaute 2 and fragile X mental retardation-related protein 1, and indirectly up-regulate the translation of a target gene.\textsuperscript{6} miRs are produced by all cell types, and the same miR may be derived from a variety of cell sources, such as endothelial cells, monocytes and macrophages, vascular smooth cells, and platelets and eventually are secreted in blood. There, degradation may be circumvented by being packaged in microparticles (exosomes, microvesicles, and apoptotic bodies) or bound with proteins or high-density lipoproteins (HDLs).\textsuperscript{7–9} In this publication, all miRs detected in plasma or serum are reviewed, independent of their cell origin or their package in microparticles and/or lipoproteins.

Several miRs were shown to take part in the pathogenesis of coronary artery disease (CAD)\textsuperscript{10,11} and atherosclerosis.\textsuperscript{12–14} Therefore, we aim to determine whether miRs in plasma and/or serum differentiate between stable and unstable CAD (or acute coronary syndromes; ACSs), unstable angina (UA) or acute myocardial infarction (AMI) within ACS, STEMI, or non-STEMI AMI, or are markers of worse outcome such as (cardiac) death. In preparing this review, the authors followed current guidance on producing high-quality systematic reviews and meta-analyses of diagnostic test accuracy, by both the Cochrane Collaboration\textsuperscript{15} and the QUADAS Group.\textsuperscript{16} As per the Cochrane Collaboration,\textsuperscript{16} when studies that lack methodological rigor or have a high risk of bias are combined in a meta-analysis, the uninformative or erroneous results can lead to wasting further resources on future research or can even lead to harm if patients are wrongly diagnosed. The authors also followed the PRISMA\textsuperscript{17} reporting guidelines for systematic reviews (see Supplementary material online, File S1). In following these standards, we aimed at providing quality evidence for the rational choice of miRs to focus on in future research, identifying the miRs with high potential for clinical applicability to distinguish patients with the disease from those without. In the second and third parts of this review, we searched for and report on mechanistic data on the clinical relevance and on the target genes of miRs with high potential identified in the first part of our study.

2. Methods

2.1 Information resources, search, and study selection

The strategy and outcome of the literature search are illustrated in Figure 1.

We searched the PubMed database for English language articles related to miRs as biomarkers in atherosclerosis, CAD, and ACS in humans, with the last search taking place on 7 October 2015. No lower date limit was used. The search strategy was performed by two independent researchers (D.G. and R.J.), encompassing a MESH search: (‘Coronary Artery Disease’ [Mesh] OR ‘Atherosclerosis’[Mesh] OR ‘Myocardial Infarction’[Mesh] OR ‘Acute Coronary Syndrome’[Mesh]) AND (‘MicroRNAs’[Mesh]) AND (Humans [Mesh] and English[lang]), identifying 412 titles. As well, a second more extended search of typical keywords was performed using: ((mir OR MicroRNA) NOT (mir[author])) AND (atherosclerosis OR CAD OR ACS OR myocardial infarction) and (plasma OR serum OR blood OR circulating OR circulation) AND (Humans[Mesh] and English[lang]) NOT (Review/Publication Type)). This text search resulted in the identification of 259 articles: with 201 articles being duplicates of the MESH search strategy and 58 new unique articles. In addition, 17 articles were identified from reference lists and author archives. From the 487 unique articles, a title screen was performed by three authors (R.N., D.G., and P.H.), and articles were excluded based on the following criteria:

- Experiments in molecular biology/biochemistry (n = 75),
- Experiments in pharmacology (n = 23),
- miR examined in cells or tissues other than blood (n = 30),
- Medical field other than cardiology (n = 56),
- Topic out of scope (though cardiology) (n = 84),
- Experiments with laboratory animals (n = 14),
- Other experiments in genetics (n = 23),
- Article is a review, editorial, comment, or interview, not an original research article (n = 64),
- Target population out of scope (n = 3).

Title screening left a total of 115 papers, which were then screened by abstract. The exclusion criteria were as follows:

- Experiments in molecular biology/biochemistry (n = 4),
- Experiments in pharmacology (n = 1),
- miR examined in cells or tissues other than blood (n = 4),
- Medical field other than cardiology (n = 1),
- Topic out of scope (though cardiology) (n = 3),
- Experiments with laboratory animals (n = 1),
- Other experiments in genetics (n = 4),
- Article is a review, editorial, comment, or interview, not an original research article (n = 25).

After abstract screening, 72 original research papers remained as being potentially relevant to this review. Of these, 3 papers were not obtainable, leaving 69 papers for full review. Data were extracted from each paper into an excel sheet, recording the main methods, results (up/down-regulation of miRs by outcome), and assessment of risk of bias, as described below.

2.2 Assessment of risk of bias for analysis and pooling of study results

Studies identified to be within the scope of this review where assessed for risk of bias by R.N., P.H., and D.G. A recent review of bias,\textsuperscript{18} as well as the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy,\textsuperscript{17,20,21} reports that there is consistent evidence of bias, with studies using a case-control design reporting higher accuracy of tests when compared with a cohort design. They also report a consistent association between the study outcome and the use of inappropriate reference standards or the biased recruitment of patients. The QUADAS-2 tool to assess quality of studies also highlights the potential bias inherent in the case-control design, patient recruitment, and use of reference standard.\textsuperscript{16} For this review, the study design, patient selection, miR index test, and reference standard were the main aspects scrutinized for risk of bias for each outcome of interest. In addition, to study the potential risk of bias across studies, data were collected on how miRs were selected for each study and on all miRs reported to have been studied, to be able to compare and contrast negative and positive results across all studies, and to identify potential bias in the selection and selective reporting of miRs studied. Disagreements on risk of bias for individual studies were discussed and a final assessment made through consensus between these three authors. Pooling of results was planned for studies with the lowest potential for bias and for studies that were sufficiently homogeneous based on miR and disease being examined.

2.3 Mechanistic data of role of miRs in progression of cardiovascular diseases

A comprehensive search of the literature was undertaken for studies that presented data on the role of the miRs that were most studied and had the
most significant associations identified in this review. The last search was undertaken in PubMed on 12 February 2012 and included the following search terms:

(MicroRNAs[Mesh]) AND (‘Coronary Artery Disease’[Mesh] OR ‘Atherosclerosis’[Mesh] OR ‘Myocardial Infarction’[Mesh] OR ‘Acute Coronary Syndrome’[Mesh])

AND

((miR-1 OR miR-133 OR miR-133a OR miR-133b OR miR-145 OR miR-208 OR miR-208a OR miR-208b OR miR-499 OR miR-499a) NOT (mir[author]))

The mechanistic studies were reviewed and mechanisms related to cardiovascular disease progression described in the results section.

2.4 Target search

To better understand the relation between miRs and their function, we screened mirTarbase database for their RNA targets. We limited RNA species for Homo sapiens for which data were validated by reporter assay analysis, qPCR, and western blot analysis were available. We looked for shared targets to suggest common pathways.

3. Results

3.1 Part 1: clinical data on diagnostic potential

Overall, out of the 69 papers reviewed in full, 19 studies were selected as having sufficient quality to assess the value of the miRs as potential biomarkers for cardiovascular disease. Data extracted from the included, missing, and excluded studies, with an appropriate study design but insufficient quality, and with a less reliable study design and insufficient quality, are available in Supplementary material online, File 2.

Due to the heterogeneity between included studies, in the study populations, settings, miRs and outcomes investigated, quantitative
Circulating microRNAs as biomarkers of cardiovascular disease

Table 1  Overview of significant miRs identified in all included studies, organized by disease progression: non-CAD vs. CAD

| Study                           | Number of patients | Tested miRs                  | Significant miRs                                      | Statistical analysis                                      |
|---------------------------------|--------------------|------------------------------|-------------------------------------------------------|----------------------------------------------------------|
| Gacorët al.²⁴                    | 16 (−); 27 (+)     | miR-1, miR-16, miR-34a, miR-122, miR-124, miR-133a/b, miR-134, miR-208b, miR-375, miR-499 | miR-34a, miR-124, miR-133a/b, miR-134 (+)               | Unadjusted non-parametric Kolmogorov–Smirnov test⁴⁴; miR-124 (P < 0.025); others (P < 0.05) |
| Gao et al.¹⁵                     | 28 (−); 167 (+)    | miR-145                      | miR-145 (−)                                            | Multivariate linear regression⁵; P < 0.0001               |
| Gao et al.¹⁶                     | 100 (−); 155 (+)   | miR-33a/b, miR-122, miR-370  | miR-122, miR-370 (+)                                    | Multivariate linear regression⁵; miR-122 (P = 0.034); miR-370 (P = 0.022) |
| Sun et al.²²                     | 36 (−); 31(+)      | miR-126                      | –                                                      | Unadjusted Mann–Whitney U or Kruskal–Wallis test⁶; P = 0.675 |
| Wang et al.³³                    | 92 (−); 154 (+)    | miR-133a                     | miR-133a (+)                                           | Multivariate linear regression⁶; P < 0.001               |
| Zhu et al.⁴⁰                     | 54 (−); 56 (+)     | miR-155                      | miR-155 (−)                                            | Unadjusted Student’s t-test⁷; P < 0.001                 |

Patient numbers and the direction of regulation of significant miRs (in parentheses) are ordered from less to more severe disease.

Traditional risk factors: age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking; blood levels of glucose and/or lipids; other blood markers and medication as specified for each study separately.

หารที่มีความแตกต่างโดยไม่ใช้ I.R.A.

 ROC AUC values are also available in the SF2 Study Quality table.

Adjusted for traditional risk factors.

No significant difference in traditional risk factors and medications taken, but significant difference in high-sensitivity C-reactive protein. However, miR-155 was not independent of age, hypertension, total C, HDL-C, LDL-C, high-sensitivity C-reactive protein, and smoking.

Pooling of study results was deemed inappropriate, and therefore a qualitative summary by miRs and disease outcome/progression is presented below. Due to lack of clarity in the results of the groups compared and results presented in Li (2015), this study was not included in the summaries below.

3.1.1 Non-CAD vs. CAD

Six original studies²⁴–²⁶,3²,3³,3⁴,4⁰ (Table 1) investigated miRs and their value in distinguishing between CAD and non-CAD patients, questioning the need for recurrent diagnostic imaging.

miR-133a,³²,³³ miR-134, miR-145,²⁵ miR-122, and miR-370²⁶ were associated with CAD presence, even after adjustment for other cardiovascular risk factors. Furthermore, their levels were positively correlated with the severity of CAD quantified by the Gensini score, in other words, may be used to predict both the presence and severity of coronary lesions in CAD patients. A single study reported miR-155⁴⁰⁻⁵⁻ being associated inversely with complicated pro-atherogenic metabolic risk factors. In separate studies, miR-126,²⁵ miR-33a/b²⁶ as well as miR-1, miR-16, miR-122, miR-208b, miR-375, and miR-499²⁴⁻²⁵ were not significantly downregulated or upregulated in CAD patients and so not suitable for discriminating CAD patients from patients without CAD.

3.1.2 Stable CAD vs. ACS

Three studies selected miRs to more accurately define stable CAD and ACS²⁵,³³,³⁷ (Table 2), miR-1, miR-21, and miR-499³³ proved to add to the diagnostic value of high-sensitive troponin (hs-Tn), a marker of cardiac injury, or in some cases be a better diagnostic biomarker than hs-Tn. miR-1, miR-499, and miR-21 significantly increased the diagnostic value in all suspected ACS patients, independent of clinical co-variants, including patient history and cardiovascular risk factors. All these miRs together with miR-145²⁵ were found to be associated with the severity of CAD. However, the biggest prognostic or diagnostic value was obtained with the combination of miR-132, miR-150, and miR-186,³⁶ even when compared with combined four classical biomarkers hsTnI, BNP, C-reactive protein (C-REACTIVE PROTEIN), and cystatin C.

3.1.3 Acute chest pain/UA vs. AMI

The major aim of five studies²²,²⁴–²⁶,3⁴,3⁵ (Table 3) was to identify superior diagnostic and prognostic markers for more accurate and timely diagnosis of UA and AMI. With the highest accuracy, miR-208a/b²²,²⁴,²⁵ stood out as the early detectable specific diagnostic marker of AMI when compared with cTnl or hs-cTnlT. miR-133a,²²,²⁵ miR-320a,²² and miR-499²²,²⁴,³⁸ also proved to be sensitive and specific AMI diagnostic biomarkers. In contrast, two studies of miR-451²²,²⁴ and single studies of miR-499,³⁵ miR-320,³⁶ and miR-16²⁴ showed no significant differences in the regulation of these miRs between comparison groups. A single population study investigated 18 miRs, with the results suggesting that only miR-126, miR-223, and miR-197²⁵ are associated with AMI disease risk. However, miR-126 and miR-197 were not tested in any of the other four studies and one other study questioning the finding of miR-223,²² as they reported not having a significant difference in regulation between UA and AMI.

3.1.4 Non-STEMI vs. STEMI

Five of the studies also investigated the ability to detect differences in levels of miRs between patients with Non-STEMI vs. STEMI²²,²⁴,²⁵,³³,³⁹ (Table 4). Previously described as potential AMI diagnostic markers, miR-133a, miR-208b²²,²⁵ as well as miR-499 and miR-451,²² and miR-134²² levels were reported as higher in STEMI, when compared with non-STEMI. In contrast, two studies of miR-499²⁴,³⁵ showed no significant difference in miR expression. A combination of miR-186 and miR-150³⁵ was reported to be sensitive and specific for the discrimination of non-STEMI cases from non-AMI controls, but not for discriminating non-STEMI from STEMI. It can be noted that STEMI
patients had significantly lower miR-145, compared with the other groups indicating an altered expression of miR-145 in these patients. In contrast, miR-223 and miR-320a, as well as miR-1, miR-21, miR-146a, miR-208a, and miR-499 were investigated in two different studies presenting mechanistic data of role of miRs in atherosclerosis and cardiovascular disease progression states and therefore have the highest potential as biomarkers. Several other recent reviews have discussed roles of miRs in atherosclerosis and cardiovascular diseases; however, in contrast, miR-134, miR-208b, and miR-320a were investigated in two different studies each with opposing results in terms of miR expression.

### 3.2 Cardiovascular disease progression

Some miRs, including miR-133a/b (5 studies), miR-208a/b (6 studies), and miR-499 (7 studies) have been well studied and found to be significant diagnostic and/or prognostic markers across different cardiovascular disease progression stages (Table 5). In most studies outperforming cTnT or hs-cTnT, miR-1 is a potential biomarker of ACS, with higher sensitivity for AMI. Another potential biomarker of ACS is miR-145, with higher sensitivity for STEMI and worse outcome of AMI.

Mid- and short-term mortality prediction was reported, with contrasting results for miR-133a and miR-208a. No firm conclusions about the potential diagnostic value of miR-21 and miR-126, miR-1, miR-146a, and miR-142-5p can be drawn because of lack of studies across different cardiovascular disease progression stages and contrasting results between studies. In contrast to miRs which were found to be associated with one or more stages in cardiovascular disease progression, miR-122 was found to be non-specific in all studies, as were miR-16 and miR-223, and miR-320a.

### 3.3 Part 2: mechanistic data of role of miRs in progression of cardiovascular diseases

After review for relevance by two study authors, the studies presenting mechanistic data are described below. We searched mechanistic data for miRs with significant associations across different cardiovascular disease progression states and therefore have the highest potential as biomarkers. Several other recent reviews have discussed roles of miRs in atherosclerosis and cardiovascular diseases.

---

**Table 2** Overview of significant miRs identified in all included studies, organized by disease progression: stable CAD vs. ACS

| Study | Number of patients | Tested miRs | Significant miRs | Statistical analysis |
|-------|-------------------|-------------|-----------------|---------------------|
| Gao et al. | 26 (–); 141 (+) | miR-145 | miR-145 | Multivariate linear regression;  P < 0.005 |
| Oerlemans et al. | 226 (–); 106 (+) | miR-1, miR-21, miR-146a, miR-208a, miR-499 | miR-1, miR-21, miR-146a, miR-208a, miR-499 (+) | |
| Zeller et al. | 48 (–); 49 (+) | miR-19a/b, miR-132, miR-140-3p, miR-142-5p, miR-150, miR-186, miR-210 | miR-19a/b, miR-132, miR-140-3p, miR-142-5p, miR-150, miR-186, miR-210 | Unadjusted Mann–Whitney test |

Patient numbers and the direction of regulation of significant miRs (in parentheses) are ordered from less to more severe disease. Traditional risk factors: age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking; blood levels of glucose and/or lipids; other blood markers and medication as specified for each study separately.

a) UA and non-STEMI combined.

b) Adjusted for traditional risk factors.

c) Twenty-four UA and 82 non-STEMI combined.

d) Also adjusted for family and CVD history and cardiac hs-TnT; overall, miR-1 and miR-21 showed the highest discriminatory power after adjustment (AUC = 0.94; 95% CI: 0.92–0.97).

e) ROC AUC values are also available in the SF2 Study Quality table.

f) Patients randomly selected from larger cohort studies and patient characteristics found comparable; miR-132, miR-150, and miR-186 showed the highest discriminatory power in validation (46 UA; 63 CAD patients) using logistic regression (AUC = 0.91; 95% CI: 0.84–0.98).
miR-1 prevented endothelial permeability in apoE KO mice and induced angiogenesis by repressing mRNA encoding seryl-tRNA synthetase. Its effect on angiogenesis was opposite to that of miR-206. In addition, miR-1-transfected embryonic stem cell enhanced cardiac myocyte differentiation and inhibited apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. miR-1 expression depended on SERCA2. Indeed, SERCA2a gene therapy of failing hearts restored miR-1 expression by an Akt/FoxO3A-dependent pathway, which is associated with normalized expression of sodium–calcium exchanger 1 (NCX) resulting in improved cardiac function.

miR-133 suppressed angiogenesis properties of endothelial cells such as proliferation rate, cell viability, and migration activity by targeting VEGFR2 and FGF1. miR-133 decreased when vascular smooth muscle cells (VSMCs) were primed to proliferate in vitro and following vascular injury in vivo, whereas it increased when VSMCs were coaxed back to quiescence in vitro and in vivo. miR-133 loss- and gain-of-function experiments showed that miR-133 plays a mechanistic role in VSMC growth. Accordingly, adeno-miR-133 reduced but anti-miR-133 exacerbated VSMC proliferation and migration in vitro and in vivo, by suppressing the transcription factor Sp-1 expression. miR-133 and miR-1, which belong to the same transcriptional unit, were decreased in mouse and human models of cardiac hypertrophy. In vitro overexpression of miR-133 or miR-1 inhibited cardiac hypertrophy. In contrast, suppression of miR-133 by ‘decoy’ sequences induced hypertrophy. In vivo inhibition of miR-133 by a single infusion of an antagonim caused marked and sustained cardiac hypertrophy. RhoA, a GDP–GTP exchange protein regulating cardiac hypertrophy; Cdc42, a signal transduction kinase implicated in hypertrophy; and Nelf-A/WHSC2, a nuclear factor involved in cardiogenesis were identified as specific targets of miR-133.

miR-145 and miR-143 were found to be co-transcribed in multipotent mouse cardiac progenitors before becoming localized to smooth muscle cells; including neural crest stem cell-derived VSMCs. miR-145 and miR-143 were down-regulated in injured or atherosclerotic vessels containing proliferating, less differentiated smooth muscle cells. Restoration of miR-145 in balloon-injured arteries via adeno virus miR-145 inhibited neointimal growth by inducing VSMC differentiation marker genes such as SM alpha-actin and calponin by up-regulating Kruppel-like factor (KLF)-5 and its downstream signalling molecule, myocardin. Transient decrease in miR-145 expression 3 days post-myocardial infarction (MI) was associated with an increase in KLF-5 and a decrease in myocardin. In vivo delivery of a miR-145 antagonist 1 day prior to and 2 and 6 days after MI, suppressed expression of KLF5 protein, decreased myofibroblast formation, and increased scar size. miR-145 was necessary for myocardin-induced reprogramming of adult fibroblasts into smooth muscle cells and sufficient to induce differentiation...
of multipotent neural crest stem cells into VSMCs. Furthermore, miR-145 and miR-143 cooperatively targeted a network of transcription factors, including KLF-4, myocardin, and ELK1, a member of ETS oncogene family, to promote differentiation and repress proliferation of smooth muscle cells. These findings demonstrated that miR-145 can direct the smooth muscle fate and that miR-145 and miR-143 function to regulate the quiescent vs. proliferative phenotype of smooth muscle cells. In addition, miR-145 and miR-143 act as communication molecules between smooth muscle and endothelial cells to enhance the angiogenic and vessel stabilization properties of endothelial cells. Angiotensin II down-regulated miR-145 and reduced KLF4 and myocardin expression in human coronary arterial smooth muscle cells. Overexpression of miR-145 and treatment with valsartan reversed KLF4 and myocardin protein expression and improved vascular injury induced by balloon injury. Mechanical stretch suppressed miR-145 expression by activating extracellular signal-regulated kinase 1/2 and up-regulating angiotensin-converting enzyme to alter VSMC phenotype, with reduced expression of contractile markers. Moreover, transcoronary gradients of miR-145-5p, and of miR-126-3p, correlated with the extent of thin-cap fibroatheromas suggesting that instable plaques may affect the local uptake or degradation of these miRs.

Data discussed above suggested a protective effect of miR-145, but other studies suggested an opposite effect. Indeed, miR-143/145 deficiency per se resulted in increased hepatic and vascular ABCA1 expression and significant reduction of atherosclerosis. Moreover, down-regulation of miR-145 protected against the development of pulmonary arterial hypertension (PAH). In patient samples of heritable PAH and idiopathic PAH, miR-145 is expressed in remodelled vessels and mutations in BMPR2 lead to up-regulation of miR-145 in mice and PAH patients.

A miR-208–MeF2 axis was found to drive the decompensation of right ventricular function in pulmonary hypertension. miR-208 inhibition, as well as tumour necrosis factor-α, activated the complex mediator of transcription 13/nuclear receptor co-repressor 1 axis, which in turn promoted MeF2 inhibition, closing a self-limiting feedback loop, driving the transition from compensating phase of right ventricle hypertrophy towards de-compensation phase. Analysis of mice lacking miR-208a indicated that miR-208a was required for proper cardiac conduction and expression of the cardiac transcription factors homeodomain-only protein and GATA4 and the gap junction protein connexin 40.

Heart function was restored in rodents by reprogramming non-myocytes into cardiomyocytes, by expressing transcription factors [GATA4, HAND2, myocyte-specific enhancer factor 2C (MEF2C), and T-box 5 (TBX5)] and miRs (miR-1, miR-133, miR-208, and miR-499) that control cardiomyocyte identity. Stimulating cardiomyocyte dedifferentiation and proliferation by activating mitotic signalling pathways involved in embryonic heart growth represents a complementary approach for heart regeneration and repair. miR-499 played an inhibiting role in the mitochondrial apoptosis pathway and had protective effects against H2O2-induced injury in cardiomyocytes.

### 3.4 Part 3: RNA targets of miRs in progression of cardiovascular diseases

In addition, we searched targets for these miRs which could give us further information about mechanism action and potential additive effects of some miRs by sharing target RNA species. Supplementary material...
Table 5 Overview of significant miRs identified in all included studies, organized by disease progression: survival vs. death

| Study                  | Number of patients | Tested miRs                                                                 | Significant miRs                                      | Statistical analysis                  |
|------------------------|--------------------|--------------------------------------------------------------------------|-------------------------------------------------------|---------------------------------------|
| Devaux et al.          | 1053 (−: 102(+))   | miR-133a, miR-208b, miR-223, miR-320a, miR-451, miR-499                   | miR-208b (+)                                          | Unadjusted ROC (AUC: 95% CI): 0.67–0.81 |
| Dong et al.            | 224(−: 22(+))      | miR-145                                                                  | miR-145 (+)                                           | Multivariate Cox regression (HR: 95% CI): 5.63: 1.99–15.91, P = 0.0012 |
| Goretti et al.         | 446(−): 64(+)+     | miR-208b, miR-499                                                         | −                                                     | Multivariate linear regression: ORs and 95% CI include 1 |
| He et al.              | 276 (−): 83 (+)+   | miR-134, miR-328                                                          | miR-134, miR-328 (+)                                  | Multivariate logistic regression (OR: 95% CI): miR-134 (2.28: 1.03–11.32, P = 0.013); miR-328 (7.35: 1.07–17.83, P = 0.004) |
| Matsumoto et al.       | 21 (−): 19 (+)     | miR-18a, miR-93, miR-125a-5p, miR-134, miR-155, miR-190b, miR-192, miR-212, miR-223, miR-331-3p, miR-380 | miR-155 (+), miR-380                                  | Mann–Whitney U test: P < 0.05 |
| Widera et al.          | 410 (−): 34 (+)+   | miR-1, miR-133a/b, miR-208a/b, miR-451, miR-499                           | miR-133a, miR-208b (+)                                | Multivariate Cox regression (HR: 95% CI): miR-133a (3.5: 1.8–7.0, P = 0.001); miR-208b (2.7: 1.4–5.3, P = 0.006) |
| Zampetaki et al.       | 21 (−): 26 (+)+    | miR-7b/e, miR-21, miR-24, miR-25, miR-28-3p, miR-93, miR-122, miR-126, miR-140, miR-146b, miR-150, miR-191, miR-197, miR-223, miR-320, miR-342-3p, miR-454, miR-486 | miR-126 (+); miR-223 (−)                             | Multivariate Cox regression (HR: 95% CI): miR-126 (2.70: 1.21–6.05, P = 0.016); miR-223 (0.37: 0.2–0.7, P = 0.002) |

Patient numbers and the direction of regulation of significant miRs (in parentheses) are ordered from less to more severe disease.

Traditional risk factors: age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking; blood levels of glucose and/or lipids; other blood markers and medication as specified for each study separately.

* = Cardiac death at 1 year; hazard regression analysis adjusted for age, circulating miR-145, cTnI, CK-MB, LVEF, eGFR, and NT-proBNP.

† = ROC AUC values are also available in the SF2 Study Quality table.

‡ = Only 6-year mortality, adjusted for traditional risk factors.

§ = Heart failure or cardiogenic death within 6 months combined, adjusted for age, gender, current smoking, hs-cTnT, NT-proBNP, and time from AMI onset to sampling.

# = Cardiac death at 1 year post-hospital discharge following MI; to adjust for confounding patients were selected from larger cohort using propensity score for logistic regression of traditional risk factors and previous MI, Killip class at admission, infarct size, reperfusion therapy, and medication at discharge.

& = All-cause 6-month mortality; significant difference in survival adjusted for age and gender. However, no significant miRs remained when Cox regression analysis included hsTnT.

* = Non-fatal vs. fatal MI within 10 years of study; adjusted for traditional risk factors and CVD history, other miRs; potentially confounded by death occurring in first vs. last 5 years for miR-126.
The microRNA-155/FOXO3a signalling pathway and its communication between vascular smooth muscle and endothelial cell to stabilize plaques (miR-145), and apoptosis (miR-1, miR-133, miR-499), which are crucial processes in the pathogenesis of cardiovascular disease. Finally, we identified shared RNA targets linking them to common functions. These functions further support their clinical relevance as diagnostic markers.

4. Discussion

Our review identified miR-1, miR-133a/b, miR-145, miR-208a/b, and miR-499(a) as the most promising miR biomarkers and/or prognostic markers for progressing stages of cardiovascular disease. Interestingly, 4 of those miRs (miR-1, miR-133, miR-208, and miR-499) were found to control cardiomyocyte identity. In addition, they share several other functions such as regulation of endothelial function and angiogenesis (miR-1, miR-133), VSMC differentiation (miR-133, miR-145), communication between vascular smooth muscle and endothelial cell to stabilize plaques (miR-145), and apoptosis (miR-1, miR-133, miR-499), which are crucial processes in the pathogenesis of cardiovascular disease. Finally, we identified shared RNA targets linking them to common functions. These functions further support their clinical relevance as diagnostic markers.

Although 19 studies were included in the review, no meta-analysis was undertaken due to the heterogeneity of the studies, including the differences across miRs and diseases studied, and also because of important differences and limitations in study design including: clinical settings, population characteristics, sample collection and handling, and qPCR normalization methods. These limitations led the research team to provide an overview of the limitations and highlight examples of good practice identified in this review, to inform future research on the methods to consider when undertaking and reporting properly designed miR biomarker studies.

### 4.1 Participant characteristics and comparison groups

Proper comparison groups are needed to be able to make a differential diagnosis. Comparing patients with disease to healthy controls has been shown to overestimate the accuracy of the diagnostic test, and in practice, clinicians are assessing and comparing patients with chest pain/disease and so need a diagnostic tool that will more accurately distinguish between diseased patients. Most studies that were excluded from the analysis compared patients with healthy controls and did not adjust for differences in metabolic profiles of patients and healthy controls, increasing the likelihood of obtaining more significant differences in miR expression between patients and controls but without adding clinical value in discriminating between patients who present with similar symptoms and metabolic profiles. Since diagnostic studies are not often able to be designed as randomized clinical trials, it is important for these studies to provide clear phenotyping of patients with known potential confounders and risk factors for disease.

Too often, adjustment for comorbidities and medication is lacking. However, information on medication is crucial in view of a recent discovery that miRs determine the efficacy of drugs, which has given rise to the field of ‘miRNA pharmacogenomics’ through ‘Pharmac-o-miRs’. Indeed, miRs play a significant role in pharmacogenomics by down-regulating genes that are important for drug function. In addition, medication affects miR expression. Statins were
Function of miRs. We identified miR-1, miR-133, miR-145, miR-208, and miR-499 as significant diagnostic and/or prognostic markers across different cardiovascular disease progression stages. They regulate endothelial function and angiogenesis (miR-1, miR-133), VSMC differentiation (miR-133, miR-145), communication between vascular smooth muscle and endothelial cell to stabilize plaques (miR-145), and regulate apoptosis in endothelial and VSMCs (miR-1, miR-133, miR-499), cardiac myocyte differentiation (miR-1, miR-133, miR-145, miR-208, miR-499), and repress cardiac hypertrophy (miR-133).

Table 7  Overview of RNA targets shared by at least two miR families

|           | CDKN1A | ETS1 | FSCN1 | HCN4 | IGF1R | LASP1 | PNP | TAGLN2 |
|-----------|--------|------|-------|------|-------|-------|-----|--------|
| miR-1-3p  | Y      |      |       | Y    |       | Y     | Y   |        |
| miR-133a-3p| Y      | Y    |       | Y    | Y     | Y     | Y   |        |
| miR-133b  | Y      | Y    |       | Y    |       | Y     | Y   |        |
| miR-145-5p| Y      | Y    |       | Y    | Y     | Y     | Y   |        |
| miR-208a-3p| Y     | Y    |       | Y    |       | Y     | Y   |        |
| miR-208b-3p| Y     |      |       |      |       | Y     | Y   |        |
| miR-499a-5p| Y     |      |       |      |       | Y     | Y   |        |
found to change the expressions of 22 whole blood miRs and 19 plasma miRs.\textsuperscript{137} Willeit and Zampetaki et al.\textsuperscript{138} found that plasma levels of platelet miRs, such as miR-223 and miR-191, and others, such as miR-126 and miR-150, decreased on platelet inhibition. It has also been shown that heparin can alter miRs in plasma, and therefore blood samples should be collected prior to heparin administration.\textsuperscript{139}

As the topic of miR in cardiology is still new and the technology is expensive, several selected studies enrolled small numbers of subjects, also limiting the generalizability of the findings.

### 4.2 Sample collection and handling

Divergence between studies may also be due to differences in sample collection and handling. However, sufficient information to reproduce and ensure high-quality sample collection and handling is often scarce in publications. In all steps when collecting whole blood, measures should be taken to prevent contamination with miRNA from intact cells and to prevent haemolysis. Hence, we recommend the National Cancer Institute’s Early Detection Research Network standard operating procedures for the collection of serum and plasma.\textsuperscript{140} The whole blood should be processed immediately. In the preparation of plasma, anticoagulants such as EDTA and citrate should be used. Heparin should be avoided because it is known to inhibit cDNA synthesis and PCR.\textsuperscript{141} Haemolysis should be screened by measuring oxyhaemoglobin absorbance at 414 nm.\textsuperscript{142} Once prepared and before freezing, plasma or serum should be centrifuged for 5 min at 3000 g to remove cells.

### 4.3 qPCR normalization methods

Divergence between studies may also be due to differences in qPCR normalization methods. These methods rely on two standard assumptions: (i) the majority of features do not vary between samples, and (ii) the proportions of up- and down-regulated expressions are approximately equal. To compensate for the lack of robustness in the existing methods, the least-variant set (LVS) normalization for mRNA arrays was developed based on data-driven housekeeping genes.\textsuperscript{143} For normalization of miR data, one can (i) identify and use several stably expressed reference miRs, or even better (ii) use the global mean expression value of all commonly expressed miRs in a given sample as normalization factor.\textsuperscript{144,147} However, only one study included in this review presented the reference miR expression levels—visually confirming that the level of the reference miR did not change between comparison groups.\textsuperscript{33} One should avoid using larger small RNA species such as U6 because they have a different biogenesis pathway and may not be secreted or protected in biofluids in the same way as miRs are.\textsuperscript{148,149} Furthermore, the use of exogenous spike-in controls to obtain standardized normalization has been considered, with seven of the included studies in this review also using an exogenous spiked in miR reference (see the SF2 Study Quality table). Recently, Roberts et al.\textsuperscript{150} compared the use of different normalization strategies for the quantification of extracellular miRs in mouse serum. The levels of the putative endogenous miRs were positively correlated with the external spike-in control, indicating that variations in the latter reflect changes in endogenous miR abundance. Furthermore, the external spike-in control was the least variable miR across all samples in the RT-qPCR array study, and between experimental groups in the time course study thus validating this normalization approach. Additionally, more miRs were statistically significant, and greater fold changes observed, when the data were normalized to the spike-in control as opposed to the average Cq. The ratio of up- and down-regulated miRs was more balanced when the data were normalized to the average Cq. But, the observation of a global shift in miR levels suggests that this ‘balance’ may be artificial.\textsuperscript{150} Several companies (e.g. Exiqon) have developed a set of synthetic spike-in RNAs which can be used to monitor the efficiency of RNA isolation, cDNA synthesis, and PCR amplification and to reveal potential presence of nucleases.

### 4.4 Selection of miRs

For this systematic review, we were only able to access data which are available in the public domain\textsuperscript{151}; it is possible that other miRs were measured in the studies and were not reported, which is supported by the reporting of nine included studies that only present data on one or two miRs. It is also possible that other miRs studies with negative results were not published at all, adding to the potential bias in identifying miRs with the best potential to support diagnosis or prognosis of cardiovascular disease. There is also inherent bias in the selection of the miRs studied, as the field is still developing, only few of the known miRs have been studied. In all but four cases in the included studies, the decision was made on insights from the previous literature, so few studies have used array technology to screen vast numbers of miRs and usually have done so for a very small number of participants. Because there are so many potential miRs to study, only a few studies have replicated similar combinations of miRs in comparable cohorts. In this review, miR-1, miR-133a/b, miR-208a/b, and miR-499(a) were studied in four or more separate studies but across different disease comparison groups and with contrasting results. Although we excluded case-control studies for reasons explained above, we want to acknowledge the importance of the pioneer studies because they have been driving miR selection. In particular, miR-1,\textsuperscript{67,68,77,82} miR-133,\textsuperscript{70} and miR-133, miR-208, and miR-499 have been studied extensively.\textsuperscript{66,69,72,88,91} Several studies\textsuperscript{24,31,37} also suggested that the diagnostic values of clusters of miRs may be higher than that of any single miR. However, cluster analysis does not provide information as to how a certain miR cluster would translate into pathogenesis or altered cellular functions in the investigated pathology.

Our approach of collating several studies allowed us to provide a list of potentially useful miRs for diagnosis of cardiovascular disease; however, a self-selection bias that arises from scientific trends to investigate similar or same hot-spot miRs by several groups cannot be excluded. Nevertheless, we conclude that such assumptions are inherently present in any secondary literature study and regard it as a benefit of our review process to make these assumptions explicit and traceable.

To prevent selective publication and selective reporting of miR research outcomes, data-sharing plans are needed, as recently proposed by the International Committee of Medical Journal Editors.\textsuperscript{152} Sharing data will increase confidence and trust in the conclusions drawn from clinical studies. It will enable the independent confirmation of results, an essential tenet of the scientific process. It may also make progress more efficient by avoiding unwanted repetition in case of reporting high-quality negative results.

### 4.5 Mirs in cells or tissues

In our review, we focused on miRs in plasma and serum and miRs examined in cells or tissues other than blood were excluded. Indeed, several miR-based studies have utilized tissues/cells for identifying miRs. But tissues other than blood (and eventually urine) are much less accessible and therefore less useful for biomarker analysis. In addition, several of our identified miRs are claimed to have tissue specificity. miR-1 is the most abundant miR specific for cardiac and skeletal muscle
and functions as a regulator of differentiation and proliferation during cardiogenesis as well as a regulator of cardiomyocyte growth in the adult heart. In human hearts of patients who had died of MI, miR-1 was up-regulated in remote myocardium when compared with infarcted tissue or healthy adult heart. Adachi et al. performed a miR array analysis in various human tissues to identify heart-specific miRs and found miR-499 almost specifically expressed in the heart, concluding that miR-499 might serve as an additional promising biomarker of MI.\textsuperscript{58,66} miR-133, which is transcribed from the same chromosomal loci as miR-1, enhances myoblast proliferation and thus is involved in cardiomyocyte proliferations.\textsuperscript{155} As shown in a mouse model, miR-208 is exclusively expressed in cardiomyocytes and consequently released during cardiomyocyte death in MI.\textsuperscript{156} Two other miRs which were identified in some studies were miR-21 and miR-126. miR-21 is up-regulated in cardiomyocytes shortly after initiation of ischaemia. However, increased expression of miR-21 in fibroblasts enhances their proliferation,\textsuperscript{157} suggesting a role of miR-21 in remodelling.\textsuperscript{158} Levels of miR-126 were up-regulated in the non-infarcted areas after induced MI in rat hearts. The effect of ischaemia reperfusion on miRs in the rat heart was evaluated by Tang et al.\textsuperscript{157} The authors found that levels of miR-1, miR-126, and miR-208 were increased, while miR-21, miR-133, and miR-195 levels had decreased. Finally, we did not identify miR-29, although members of the miR-29 family were down-regulated in the region adjacent to MI areas in mice and humans.\textsuperscript{160}

As stated earlier, miRs in plasma avoid degradation by being packaged in microvesicles (exosomes, microvesicles, and apoptotic bodies) or by being bound with proteins or HDLs.\textsuperscript{161} In inflammatory microvesicles, miR-133 was among the most interesting miRs in association with metabolic and cardiovascular diseases, together with the let-7 family, miR-17/92 family, miR-21, miR-29, miR-126, miR-133, miR-146, and miR-155.\textsuperscript{14} Other miRs were also identified as potential markers in plasma or serum, such as miR-126 predicted the occurrence of cardiovascular events in patients with stable CAD.\textsuperscript{51} Independent study revealed a significant reduction of miR-126 expression in circulating microvesicles in patients with stable CAD with and without diabetes mellitus.\textsuperscript{162} A group of miRs, including miR-21 and miR-126, were up-regulated in microvesicles isolated from the plasma of UA patients compared with controls.\textsuperscript{151} In addition, miRs control the expression of most of the genes associated with HDL metabolism, including the ATP transporters, ABCA1, SRB1, etc. These findings suggest that miRs regulate HDL biogenesis, cellular cholesterol efflux, and HDL cholesterol uptake in the liver, thereby controlling all of the steps of reverse cholesterol transport, likely to be associated with cardiovascular disease.\textsuperscript{163} For example, expression of ABCA1, associated with HDL, is highly regulated at the post-transcriptional level by multiple miRs, including miR-145, miRs also regulate the expression of LXRs (liver X receptors), thereby controlling the transcriptional activation of ABCA1. LXRs are directly targeted by miR-1 together with miR-206, miR-613, and miR-155.\textsuperscript{164} In addition, HDL can transport miRs and deliver them to the receiving cells influencing their gene expression. Hence, it has been suggested that future studies should include data on miR expression in HDL particles or microvesicles. However, requirement of a high volume of plasma to isolate HDL and/or microvesicles and the current time consuming and expensive extraction procedures render such studies very unlikely, at least in the near future. Nevertheless, as seen in the studies included in this review, little or no information about presence in solution or package in HDL or microparticles was disclosed. Therefore, these data warrant further investigation of the potential of microvesicles as putative biomarkers and as novel carriers for the cell-specific transfer of miRs and other therapeutic agents.

### 4.6 Prognostic research

Further research is required and should concentrate on determining the prognostic value of miR deregulations before the onset of clinical cardiovascular symptoms. All studies in this review, except one, determined the association of miRs with the cardiovascular disease state at the time of blood sampling, and because of lack of follow-up of the patients, did not determine prognostic value of miRs to identify new events in addition to other risk factors. In order to do that, large-scale studies with longer patient follow-up periods are needed. This is where blood samples collected in biobanks could be useful as they represent both healthy and diseased populations. As blood samples in biobanks were collected with no particular goal initially, a majority of them are not suitable for detection of miRs other than in plasma or serum.

In conclusion, we reviewed the deregulated circulating miRs which may be useful for future miR research using blood samples from biobanks worldwide. We applied a systematic review approach to identify miRs which are more likely to be associated with CVD. Finally, we identified major limitations in current miR research and provided an overview of several aspects researchers should consider to prepare the highest-quality future studies and publications possible. Certainly, large-scale and standardized (references, adjustment for established cardiovascular and metabolic factors and medications) follow-up studies are needed to establish the prognostic value of miRs. Summarizing the most promising miRs, also by linking them to target genes implied in the development of CVD, could also be helpful in designing these future studies.

### Supplementary material

Supplementary material is available at Cardiovascular Research online.

### Acknowledgements

Would like to thank Dr Heinrich Huber for his input into the development of this study and Ms Ambra Pastori for a critical review of the data and score tables.

### Conflict of interest: none declared.

### Funding

This work was supported by the European Social Fund under the Global Grant measure (VI1-3.1-SMM-07-K-03-041) and grants from the Bijzonder Onderzoeksfonds of the KU Leuven (PF/10/014), and the Interdisciplinary Ontwikkelingsfonds—Kennisplatform (KP/12/009). Funding to pay the Open Access publication charges for this article was provided by provided by Interdisciplinary Ontwikkelingsfonds—Kennisplatform (KP/12/009)-KU Leuven.

### References

1. Ling H, Fabbi M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847–865.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–297.
3. Lytle JR, Yaroi TA, Steitz JA. Target miRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci U S A 2007;104:9667–9672.
4. Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008;30:460–471.
5. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008;455:1124–1128.
6. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007;318:1931–1934.
7. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H,
31. Oerlemans MIFJ, Mosterd A, Dekker MS, de Vrey EA, van Mil A, Pasterkamp G, R. Navickas

30. Matsumoto S, Sakata Y, Nakatani D, Suna S, Mizuno H, Shimizu M, Usami M, Sasaki T, Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology.

29. Dong Y-M, Liu X-X, Wei G-Q, Da Y-N, Cha L, Ma C-S. Prediction of long-term outcome after acute myocardial infarction using circulating miR-145.

28. Zhou G-F, Yang L-X, Guo R-W, Liu H, Shi Y-K, Ye J-S, Yang Z-H. MicroRNA-155 is inversely associated with severity of coronary stenotic lesions calculated by the Gensini score. Coron Artery Dis 2014;25:304–310.

27. Zhang R, Lan C, Pei H, Duan G, Huang L, Li L. Expression of circulating miR-486 and miR-150 in patients with acute myocardial infarction. BMC Cardiovasc Disord 2015;15:51.

26. Zhang L, Chen X, Su T, Li H, Huang Q, Wu D, Yang C, Han Z. Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction. J Thorac Dis 2013;5:308–313.

25. Zhang R, Lan C, Pei H, Duan G, Huang L, Li L. Expression of circulating miR-486 and miR-150 in patients with acute myocardial infarction. BMC Cardiovasc Disord 2015;15:51.

24. Zhang L, Chen X, Su T, Li H, Huang Q, Wu D, Yang C, Han Z. Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction. J Thorac Dis 2013;5:308–313.

23. Dong Y-M, Liu X-X, Wei G-Q, Da Y-N, Cha L, Ma C-S. Prediction of long-term outcome after acute myocardial infarction using circulating miR-145.

22. Zhou G-F, Yang L-X, Guo R-W, Liu H, Shi Y-K, Ye J-S, Yang Z-H. MicroRNA-155 is inversely associated with severity of coronary stenotic lesions calculated by the Gensini score. Coron Artery Dis 2014;25:304–310.

21. Qi Q, Jiang Q, Yan W, Li X, Zhang M, Peng P, Shao M, Chen L, Zhu H, Tian N. Expression of circulating microRNAs in patients with ST segment elevation acute myocardial infarction. Minerva Cardioangiol 2015;63:397–402.

20. Liang J, Bai S, Lu L, Li C, Wu J, Xia Z, Xu D. A subset of circulating microRNAs is expressed differently in patients with myocardial infarction. Mol Med Rep 2015;12:243–247.

19. Whiting PF. Rutjes AWJS, Westwood ME, Mallett S. A systematic review classifies sources of bias and variation in diagnostic test accuracy studies. J Clin Epidemiol 2013;66:1093–1104.

18. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.

17. Huber Hj, Holvoet P. Exosomes: emerging roles in communication between blood cells and vascular tissues during atherosclerosis. Curr Opin Lipidol 2015;26:412–419.

16. Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res 2013;99:284–293.

15. Hettinger AJ, D’Souza SN. The microRNA-mRNA network: a central player in pathologic progression of cardiovascular disease. J Clin Invest 2013;123:53–63.

14. Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res 2013;99:284–293.

13. Huber Hj, Holvoet P. Exosomes: emerging roles in communication between blood cells and vascular tissues during atherosclerosis. Curr Opin Lipidol 2015;26:412–419.

12. Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res 2013;99:284–293.

11. Hettinger AJ, D’Souza SN. The microRNA-mRNA network: a central player in pathologic progression of cardiovascular disease. J Clin Invest 2013;123:53–63.

10. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology.

9. Mitchell PS, Parkin RK, Kroh EM, Fritz L, Parkin RK, Kroh EM, Fritz L, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

8. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

7. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

6. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

5. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

4. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

3. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

2. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

1. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

Shang X, Gong T, Ying G, Wang J, Zen K, Zhang J, Zhang C-Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Carc Res 2008;68:109–117.

8. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

7. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

6. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

5. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

4. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

3. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

2. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.

1. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Mitchell PS, Parkin RK, Kroh EM, Fritz L. The expression of circulating microRNAs in patients with coronary artery disease.
Circulating microRNAs as biomarkers of cardiovascular disease

55. Li C, Fang Z, Jiang T, Zhang Q, Liu C, Zhang C, Xiang Y. Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myocardial disease and angiogenesis. BMC Genomics 2013;14:161.

56. Li Y-Q, Zhang M-F, Wen H-Y, Hu C-L, Liu R, Wei H-Y, Ai C-M, Wang G, Liao X-X, Li X. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clio São Paulo Braz 2013;67:85–90.

57. Li S, Ren J, Xu N, Zhang J, Geng Q, Cao C, Lee C, Song J, Liu J. Chen H. MicroRNA-19b functions as potential anti-thrombotic protector in patients with unstable angina by targeting tissue factor. J Mol Cell Cardiol 2014;47:59–57.

58. Olivieri F, Antonicelli R, Lorenzini M, D’Alessandra Y, Lazzarini R, Santini G, Spazafumo L, Lia S, De Carlo A, Galazette R, Rezzonico R, Testa R, Pomigliano G,Capogrossi MC, Procopio AD. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non-ST-elevation myocardial infarction. Int J Cardiol 2013;167:531–536.

59. Peng L, Chuang-guan Q, Bei-fang L, Xue-zhi D, Zi-hao W, Yun-fu L, Yan-ping D, Yang-gui L, Wei-guo L, Tian-yang H, Zhen-wen H. Clinical impact of circulating miR-133, miR-129 and miR-66B in plasma of patients with acute myocardial infarction. Diagn Pathol 2014;9:89.

60. Peng L, Chun-guang Q, Bei-fang L, Xue-zhi D, Zi-hao W, Yun-fu L, Yan-ping D, Yang-gui L, Wei-guo L, Tian-yang H, Zhen-wen H. Clinical impact of circulating miR-133, miR-129 and miR-66B in plasma of patients with acute myocardial infarction. Diagn Pathol 2014;9:89.

61. Pirola AP, Cordeddu L, Cameron VA, Frampton CM, Troughton RW, Doughty RN, Whalley GA, Ellis CJ, Yandle TG, Richards AM, Foo R-S. Circulating miR-33-3p and miR-122 as candidate markers for the presence and progression of coronary artery syndromes. Int J Cardiol 2014;167:375–385.

62. Sun Q, Jin X, Gao J, Zhang P, Mou W, Yang C, Tong H, Wen H, Wen X, Tian Y. Identification and characterization of novel serum microRNAs in unstable angina pectoris and subclinical atherosclerotic patients. Exp Cell Res 2015;333:220–227.

63. Vogel B, Keller A, Frese KS, Kloos W, Kayvanpour E, Sedaghat-Hamedani F, Hassel S, Marquet S, Beuer M, Giannitsis E, Hardt S, Katus HA, Meder B. Refining diagnostic miRNA signatures by whole-miRNome kinetic analysis in acute myocardial infarction. Exp Cell Res 2013;359:410–418.

64. Wang F, Long G, Zhao C, Li H, Chaugui S, Wang Y, Chen C, Wang DW. Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction. Plos One 2014;9:e105734.

65. Ward JA, esa N, Priditi K, Freedman JE, Keaney JF, Tanwervee K, Vitsvee O, Ambrvo R, Lee R, Mcmanus DD. Circulating cell and plasma microRNA profiles differ between non-ST-segment and ST-segment-elevation myocardial infarction. Fam Med Med Sci 2013;10:227–228.

66. Adachi T, Nakashini M, Otsuba Y, Nishimura K, Hirokawa G, Goto Y, Nonogi H, Iwata S, Tanaka C. Plasma microRNA-499 as a biomarker of acute myocardial infarction. Clin Chem 2013;60:1183–1185.

67. Aj J, Zhang R, Li Y, Yu F, Liu Y, Jao J, Li K, Yu B, Li Z, Wang R, Wang L, Li Q, Wang N, Shan H, Li Z, Yang B. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010;391:73–77.

68. Cheng Y, Tan N, Yang J, Liu X, Gao X, He P, Dong X, Qin S, Zhang C. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci 2010;119:89–97.

69. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Deusy V, Hofstra L, Wagner DR, Stassen JA, Heymans S, Schroen B. Circulating MicroRNA-208a and MicroRNA-208b associated with acute myocardial infarction. Plos One 2014;9:e105734.

70. Hulsmans M, De Keyser D, Holvoet P. MicroRNAs regulating oxidative stress and inflammation in patients with coronary artery disease. J Mol Med 2013;11:34–38.

71. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Ruldoff J, Leipinger P, Meese E, Katus HA, Rottbauer W. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2011;106:13–23.

72. Sayed ASM, Xia K, Li F, Deng X, Salma U, Li T, Deng H, Yang Z, Hanyong T, Peng J. The diagnostic value of circulating microRNAs for middle-aged (40–60-year-old) coronary artery disease patients. Clio São Paulo Braz 2015;170:257–263.

73. Stather PW, Sylvius N, Wild JB, Choke E, Sayers RD, Bown MJ. Differential microRNA expression profiles in peripheral arterial disease. Cardiovasc Res 2013;2:490–497.

74. Wang R, Li N, Zhang Y, Ran Y, Pu J. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. Intern Med Tokyo Jul 2011;50:1789–1795.

75. Wang J, Ye P, Zhong Y, Jiang S, Shao J, Gong J, Altered serum microRNAs as novel diagnostic biomarkers for atypical coronary artery disease. Plos One 2014;9:e107012.

76. Weber M, Baker MB, Patel RS, Quyyumi AA, Bao G, Searles CD. MicroRNA expression profile in CAD patients and the impact of ACEI/ARB. Cardiol Res Pract 2011;2011:1–5.

77. Zhao CH, Cheng G-C, He RL, Hong Y, Wan QL, Wang Z-Z, Pan Z-Y. Analysis and clinical significance of microRNA-499 expression levels in serum of patients with acute myocardial infarction. J Nat Res Med 2015;14:4027–4034.

78. Zhong J, He Y, Chen W, Shui X, Chen L, Wei L. Circulating microRNA-19a as a potential novel biomarker for diagnosis of acute myocardial infarction. Int J Mol Sci 2014;15:20355–20364.

79. Weltin SM, Goossens EAC, Quax PHA, Nossent AY. The multifactorial nature of micro-RNAs in vascular remodelling. Cardiovasc Res 2016;110:6–22.

80. Zellin P, Price NA, Poeckel T, Fernández-Hernando C, microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis 2016;246:352–360.

81. Dai Y, Condorelli G, Mehta JL. Scavenger receptors and non-coding RNAs: relevance in atherogenesis. Cardiovasc Res 2016;109:24–33.

82. Economou EK, Oikonomou E, Siasos G, Papageorgeou N, Tsalandris S, Moumouzi K, Papaioannou S, Toussoulis D. The role of microRNAs in coronary artery disease: from pathophysiology to diagnosis and treatment. Atherosclerosis 2015;241:624–633.

83. Schober A, Nazary-Jahantigh M, Weber C. MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis. Nat Rev Cardiol 2015;12:361–374.

84. Romaine SPR, Tomaszewski M, Condorelli G, Samani NJ. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart 2015;101:921–928.

85. Hulsmans M, De Keyzer D, Holvoet P. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J Of Publ Fed Am Soc Exp Biol 2011;25:3151–3167.

86. Wang H, Zhu H-Q, Wang F, Zhou Q, Gui S-Y, Wang Y. MicroRNA-1 prevents high-fat diet-induced endothelial permeability in apoe knock-out mice. Mol Cell Biochem 2013;378:153–159.

87. Lin C-Y, Lee H-C, Fu C-Y, Ding Y-Y, Chen J-S, Lee M-H, Huang W-J, Tsai H-J. MiR-1 and miR-206 target different genes to have opposing roles during angiogenesis in zebrafish embryos. Nat Commun 2013;4:2829.

88. Soloviev S, Suarez Y, Lu J, Mishima Y, Giraldez AJ. MiR-1 and miR-206 target different genes to have opposing roles during angiogenesis in zebrafish embryos. Nat Commun 2013;4:2829.

89. Glass C, Singh DK. MicroRNA-1 transfected embryonic stem cells enhance cardiac myocyte differentiation and inhibit apoptosis by modulating the Pten/Akt pathway in the infarcted heart. J Appl Heart Physiol 2013;101:H2038–H2049.
gene transcription in vascular smooth muscle cells phenotypic switch in vitro and vascular remodeling in vivo. Circ Res 2011;109:880–893.

9. Care A, Catellani D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segalini P, Gu Y, Dalton ND, Elia L, Latornico MVG, Haydal M, Autero C, Russo MA, Dorn GW, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13:618–625.

10. Wistuba D, Li S-H, Guo J, Miao A, Wu J, Sun L, Davis K, Wessel RD. Li R-K. Role of miR-145 in cardiac myofibroblast differentiation. Mol Cardiol 2016;9:64–95.

11. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee T-H, Miano JM. Ivey KN, Srivastava D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2007;446:705–710.

12. Ciminet M, Quintavalle M, Miragoli M, Chen J, Condorelli G, Elia L. TGF-beta triggers miR-145/146 transfer from smooth muscle cell to endothelial cells, thereby modulating vessel stabilization. Circ Res 2011;109:1753–1761.

13. Cheng Y, Liu X, Yang J, Lin Y, Xu D-Z, Lu Q, Deitch EA, Huo Y, Dolph H, Esz C, Zhang M. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009;105:158–166.

14. Shyu K-G, Cheng W-P, Wang B-W. Angiotensin II downregulates microRNA-145 to regulate Kruppel-like factor 4 and myocardin expression in human coronary arterial smooth muscle cells under high glucose conditions. Circ Res 2010;106:103–112.

15. Li A, Yang Q, Yang K. miR-133a mediates the hypoxia-induced apoptosis by inhibiting p21WAF1/CIP1. Mol Cell Biochem 2010;337:103–109.

16. Gao S, Wassmer M, Zhang L, Li Y, Wang J, Zhang Y, Sheih H, Williams J, Geng Y-J. MicroRNA-133a regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis. Atherosclerosis 2014;222:171–179.

17. Li M, Chiu J-F, Gagne J, Fukagawa K. Age-related differences in insulin-like growth factor-1 receptor signal transduction in eukaryotic cells. Eur J Cell Physiol 2008;217:377–387.

18. Qa’aty N, Wang Y, Mao S, Vincent M, Husain A, Hinek A. The anti-diabetic hormone glucagon-like peptide-1 induces formation of new elastic fibers in human cardiac fibroblasts after cross-activation of IGF-IR. Endocrinology 2015;156:90–102.

19. Warboys CM, de Luca A, Amini N, Luong L, Dulcke H, Hisao S, White A, Biewas S, Khamis R, Chong CK, Cheung W-M, Sherwin SJ, Bennett MR, Gil J, Mason JC, Haskard D, Evans P. Fusion promoting cardiomyogenic differentiation via a p53-dependent pathway. Atherosclerosis Thrash Vasc Biol 2014;34:985–995.

20. Spineti G, Cordella D, Fortunato O, Sangalli E, Losa S, Gott A, Carnelli F, Rosa F, Riboldi S, Fesca A, Feltri E, Mareschi A, Mamed A. Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the miR-15/105-3P-FOXO3a signaling pathway. Circ Res 2013;112:510–522.

21. Kaudewitz D, Zampetaki A, Mayor P. MicroRNA biomarkers for coronary artery disease? Eur Atheros Rep 2015;17:70.

22. Rukav JL, Wiltencia J, Falle J, Vinterh J, Shimomuro N. Pharmacor-mR. linking micro-RNAs and drug effects. Brief Bioinform 2014;15:648–659.

23. Li J, Chen H, Ren J, Song J, Zhang F, Zhang J, Lee C, Li G, Geng C, Cao C, Xu N. Effects of statin on circulating microRNAome and predicted function regulatory network in patients with unstable angina. BMC Med Genomics 2015;8:425.

24. Williet P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirsby NS, Crosby-Nwaobi R, Prokopi M, Drozdoz I, Langley SR, Saxpavas S, Markus HS, Mitchell JA, Warner TD, Kiehl S, Mayor P. MicroRNA-145 as biomarkers for platelet activation. Circ Res 2013;112:595–600.

25. Kaudewitz D, Lee R, Williet P, McGregor R, Markus HS, Kiehl S, Zampetaki A, Storey RF, Channon KM, Mayor P. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Res 2013;130:609–615.

26. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Kneuer KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE. Standard operating procedures for serum and plasma collection: early detection research network consensus statement. Stand- ard Operating Procedure Integration Working Group. J Proteome Res 2009;8:113–117.

27. Garcia ME, Bianco JL, Cabrillo J, Gargallo-Viola D. Anticoagulants interfere with PCR process. J Clin Microbiol 2002;40:1567–1568.

28. Biondal T, Jensby Nielsen S, Baker A, Andreaesn D, Mouriten P, Wang Teilm, Dahlviesen K. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 2013;59:51–56.

29. Calza S, Valentini D, Pavitan Y. Normalization of oligonucleotide arrays based on the least-varient set of genes. BMC Bioinformatics 2009;10:140.

30. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Spelman F, Vandesompele J. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009;10:R64.

31. Hellemans J, Mortier G, De Paepe A, Spelman F, Vandesompele J. qbase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007;8:R19.

32. D’haene B, Mestdagh P, Hellemans J, Vandesompele J. RNA expression profiling: reference genes to global mean normalization. In: Fan J, ed. Next-Generation MicroRNA Expression Profiling Technology. Totowa, NJ: Humana Press; 2012. 261–272.

33. Schlosser K, McIntyre LA, White RJ, Stewart DJ. Customized internal reference controls for improved assessment of circulating microRNAs in disease. Jeyaseelan K, ed. PLoS One 2015;10:e0127744.

34. Groeneveld EE, Tijsen AJ, van den Boss P. MicroRNA RT-qPCR. Circ Res 2014;115:210–214.

35. Roberts TC, Coenen-Stass AML, Wood MA. Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in serum. Mol Oncol 2015;9:803–827.

36. Kolechkov EA. Zaporochnichka IA, Morozzin ES, Bryzunova OE, Vlasov VV, Laktionov PP. Protocol for miRNA isolation from biofluids. Anot Biochem 2016;49:894–899.

37. Taichman DB, Backus J, Baethge C, Bauchner H, de Leeuw PW, Drazen JM, Fletcher J, Frizzle FA, Groves T, Haileamlak A, James A, Laine C, Pepier L, Pinborg A, Sahni P, Sahu B. Sharing clinical trial data: a proposal from the international committee of medical journal editors. JAMA 2016;315:467–468.

38. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific micro-RNA that targets Hnd2 during cardiogenesis. Nature 2005;436:214–220.

39. Bostjancic E, Zidar N, Stajner D, Glavac D. MicroRNA mir-1 is up-regulated in remote myocardium in patients with myocardial infarction. Folia Bioi (Praho) 2010;56:27–31.
155. Chen J-F, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang D-Z. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006;38:228–233.

156. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007;316:575–579.

157. Ye Y, Perez-Polo JR, Qian J, Birnbaum Y. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics 2011;43:534–542.

158. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, Wang D, Krall TJ, Delphin ES, Zhang C. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009;284:29514–29525.

159. Tang Y, Zheng J, Sun Y, Wu Z, Liu Z, Huang G. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J 2009;50:377–387.

160. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008;105:13027–13032.

161. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423–433.

162. Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, Wenzel D, Vosen S, Franklin BS, Fleischmann BK, Nickenig G, Werner N. Endothelial microparticle-mediated transfer of microRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 2013;128:2026–2038.

163. Canfrán-Duque A, Ramírez CM, Goedeke L, Lin C-S, Fernández-Hernando C. MicroRNAs and HDL life cycle. Cardiovasc Res 2014;103:414–422.

164. Jiang H, Huang S, Li X, Li X, Zhang Y, Chen Z-Y. Tyrosine kinase receptor B protects against coronary artery disease and promotes adult vasculature integrity by regulating Ets1-mediated VE-cadherin expression significance. Arterioscler Thromb Vasc Biol 2015;35:580–588.